Back to top
more

bluebird bio, Inc. (BLUE)

(Delayed Data from NSDQ)

$28.12 USD

28.12
8,244,998

+2.20 (8.49%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss

bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.

Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).

bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies

bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for January 21st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag

Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.

Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY

The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.

bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity

bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.

J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug

J&J (JNJ) initiates the rolling submission of its BLA to the FDA for BCMA CAR-T therapy, ciltacabtagene autoleucel to treat adults with relapsed/refractory multiple myeloma.

Bluebird (BLUE) Down 3.8% Since Last Earnings Report: Can It Rebound?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss

bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of 4.23% and -25.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards?

Sorrento (SRNE) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Will Bluebird Bio (BLUE) Report Negative Q3 Earnings? What You Should Know

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA

bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.

bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA

The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.

Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Bluebird (BLUE) Down 7.8% Since Last Earnings Report: Can It Rebound?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BioNTech (BNTX) to Report Q2 Earnings: What's in Store?

During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.

MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?

MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Why Earnings Season Could Be Great for bluebird bio (BLUE)

bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results